Skip to main content

Cencora Prices $3 Billion Senior Notes Offering

Tipranks - Tipranks - Sat Feb 14, 4:02PM CST

Valentine's Day Sale - 70% Off

Cencora ( (COR) ) has provided an announcement.

On February 13, 2026, Cencora closed a $3.0 billion underwritten public offering of unsecured, unsubordinated senior notes with maturities ranging from 2029 to 2056 and coupons between 3.950% and 5.650%. The notes, issued under existing indentures with U.S. Bank Trust Company as trustee, rank pari passu with Cencora’s other unsecured debt and are structurally subordinated to obligations of its subsidiaries.

The company plans to use the proceeds primarily to repay borrowings under a 364-day term credit agreement that financed part of its acquisition of oncology platform OneOncology, with any remaining funds earmarked for general corporate purposes. The transaction refines Cencora’s capital structure by terming out acquisition-related bank debt into longer-dated bond financing, potentially reducing refinancing risk and reinforcing its balance sheet for stakeholders.

The indentures impose customary covenants limiting the creation of certain liens and sale-leaseback transactions, and restrict mergers, consolidations, or major asset sales involving the company and its restricted subsidiaries. They also define standard events of default, under which holders of at least 25% of each note series’ principal amount, together with the trustee, may accelerate the notes if Cencora fails to meet payment or other obligations.

The most recent analyst rating on (COR) stock is a Buy with a $425.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.

Spark’s Take on COR Stock

According to Spark, TipRanks’ AI Analyst, COR is a Neutral.

The score is driven primarily by solid operating/cash-flow performance and favorable technical momentum, tempered by balance-sheet leverage risk and a high P/E with a low dividend yield. Earnings call tone was constructive with raised guidance, but higher interest expense and near-term cash flow seasonality cap upside.

To see Spark’s full report on COR stock, click here.

More about Cencora

Cencora, Inc. is a leading global pharmaceutical solutions organization that partners with drug manufacturers and healthcare providers to facilitate and optimize market access to therapies for people and animals. The Fortune 500 company, which generates more than $300 billion in annual revenue, focuses on secure, reliable distribution of pharmaceuticals, healthcare products, and related services worldwide.

Headquartered in Conshohocken, Pa., Cencora employs more than 51,000 people globally and positions itself at the center of the pharmaceutical value chain. Its scale and logistics capabilities make it a critical intermediary between pharmaceutical innovators and care providers, underpinning its ranking as #10 on the Fortune 500 and #18 on the Global Fortune 500.

Average Trading Volume: 1,403,802

Technical Sentiment Signal: Buy

Current Market Cap: $71.14B

Learn more about COR stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Trending Articles

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).